Thermo Fisher Scientific Invests $40 Million to Expand Bioprocessing Manufacturing Site
Thermo Fisher Scientific is expanding its Millersburg, Penn., site with a $40 million investment to support increased production of single-use technology for critical vaccines and biologics.
On Feb. 15, 2022, Thermo Fisher Scientific announced that it is investing $40 million to expand its single-use technology manufacturing facility in Millersburg, Penn. The expansion is part of a $650 million multi-year investment to enhance the company’s ability to provide flexible, scalable, and reliable bioprocessing production capacity. Thermo Fisher announced the multi-year investment in 2021. The expanded capacity will be for manufacturing critical materials used in developing new and existing biologics and vaccines, including for COVID-19.
Thermo Fisher has been expanding the Millersburg facility over the past two years after the facility was initially acquired in 2015. That first phase of expansion included the modernization of warehouse space and clean rooms. The second phase of expansion will include a new 47,000-ft2 warehouse and the creation of 100 new jobs at various levels. The facility is expected to be fully renovated by mid-2023 and will employ more than 1000 people upon completion.
“Since the start of the pandemic, the Millersburg site has been instrumental in supporting more than 20 pharmaceutical partners developing lifesaving therapies and vaccines,” said Mitch Kennedy, president, single use technologies, Thermo Fisher Scientific, in a company press release. “During the pandemic, our colleagues in Millersburg and around the world answered the call for increased production. Our expanded bioprocessing capabilities will ensure that we can continue to deliver essential supplies to our customers as demand surges.”
Source: Thermo Fisher Scientific
